- •Foreword
- •Preface
- •Acknowledgements
- •Contents
- •Contributors
- •Summary: An Introduction to Mohs Micrographic Surgery
- •1.1 Introduction
- •Summary: Conclusion
- •1.2 Conclusion
- •References
- •Summary: Introduction
- •2.1 Introduction
- •Summary: Common Indications
- •2.2 Common Indications
- •2.2.1 Basal Cell Carcinoma (BCC)
- •2.2.2 Squamous Cell Carcinoma (SCC)
- •Summary: Uncommon Indications
- •2.3 Uncommon Indications
- •2.3.2 Microcystic Adnexal Carcinoma (MAC)
- •2.3.3 Atypical Fibroxanthoma (AFX)
- •2.3.5 Malignant Fibrous Histiocytoma (MFH)
- •2.3.6 Sebaceous Carcinoma (SC)
- •2.3.7 Melanoma
- •2.3.8 Merkel Cell Carcinoma (MCC)
- •Summary: Conclusion
- •2.4 Conclusion
- •References
- •3: Preoperative Evaluation
- •Summary: Introduction
- •3.1 Introduction
- •3.3 History of Present Illness and Physical Examination
- •Summary: Past Medical History
- •3.4 Past Medical History
- •Summary: Medications and Allergies
- •3.5 Medications and Allergies
- •Summary: Assessing the Need for Infection Prophylaxis
- •Summary: Discussion of Postoperative Care
- •3.7 Discussion of Postoperative Care
- •Summary: Conclusion
- •3.8 Conclusion
- •References
- •Summary: Introduction
- •4.1 Introduction
- •Summary: Mohs Surgery Waiting Room
- •4.2 Mohs Surgery Waiting Room
- •4.3 Mohs Surgery Operative Room Planning
- •4.3.1 Photography
- •4.3.2 Laser Safety
- •4.4 Mohs Surgery Operative Room Equipment
- •4.4.1 Surgical Table
- •4.4.3 Surgical Lights
- •4.4.4 Surgical Sink
- •4.4.5 Electrosurgical Equipment
- •4.4.6 Suction
- •4.4.7 Mayo Stand/Kick Bucket
- •4.4.8 Waste Disposal
- •Summary: Personal Protective Equipment
- •4.5 Personal Protective Equipment
- •4.5.1 Masks and Eye Protection
- •4.5.2 Gowns
- •4.5.3 Scrubs
- •4.5.4 Gloves
- •Summary: Instrumentation and Setup
- •4.6 Instrumentation and Setup
- •4.6.1 Scalpels
- •4.6.2 Blades
- •4.6.3 Standard Mohs Surgery Setup
- •4.6.4 Mohs Surgery Eye Tray
- •4.6.5 Excision/Closure Tray for Face
- •4.6.6 Excision/Closure Tray for Trunk
- •4.6.7 Nail Surgery Instruments
- •Summary: Wound Care Dressing Materials
- •4.7 Wound Care Dressing Materials
- •Summary: Equipment Sterilization
- •4.8 Equipment Sterilization
- •Summary: Monitoring and Emergency Equipment
- •4.9 Monitoring and Emergency Equipment
- •Summary: Conclusion
- •4.10 Conclusion
- •References
- •Summary: Introduction
- •5.1 Introduction
- •Summary: History
- •5.2 History
- •Summary: Pharmacology
- •5.3 Pharmacology
- •Summary: Pharmacokinetics
- •5.4 Pharmacokinetics
- •Summary: Regional Anesthesia
- •5.5 Regional Anesthesia
- •Summary: Peripheral Nerve Fibers
- •5.6 Peripheral Nerve Fibers
- •Summary: Metabolism
- •5.7 Metabolism
- •Summary: Toxicity
- •5.8 Toxicity
- •Summary: Method of Injection
- •5.9 Method of Injection
- •Summary: Amino-Esters
- •5.10 Amino-Esters
- •Summary: Amino-Amides
- •5.11 Amino-Amides
- •5.11.1 Topical Anesthesia
- •Summary: Conclusion
- •5.12 Conclusion
- •References
- •Summary: Introduction
- •6.1 Introduction
- •Summary: Scalp and Forehead
- •6.2 Scalp and Forehead
- •6.2.1 Vasculature
- •6.2.2 Nerves
- •6.2.3 Lymphatic Drainage
- •Summary: Midface
- •6.3 Midface
- •6.3.1 Nasal Subunit
- •6.3.1.1 Vasculature
- •6.3.1.2 Nerves
- •6.3.1.3 Lymphatic Drainage
- •6.3.2 Perioral
- •6.3.2.1 Vasculature
- •6.3.2.2 Nerves
- •6.3.2.3 Lymphatic Drainage
- •6.3.3 Chin
- •6.3.3.1 Vasculature
- •6.3.3.2 Nerves
- •6.3.3.3 Lymphatic Drainage
- •Summary: Periorbital
- •6.4 Periorbital
- •6.4.1 Vasculature
- •6.4.2 Nerves
- •6.4.3 Lymphatic Drainage
- •Summary: Cheeks
- •6.5 Cheeks
- •6.5.1 Vasculature
- •6.5.2 Nerves
- •6.5.3 Lymphatic Drainage
- •Summary: Auricular
- •6.6 Auricular
- •6.6.1 Vasculature
- •6.6.2 Nerves
- •6.6.3 Lymphatic Drainage
- •Summary: Neck
- •6.7 Neck
- •6.7.1 Nerves
- •6.7.2 Lymphatic Drainage
- •6.8 Special Anatomic Considerations in Mohs Micrographic Surgery
- •6.8.1 Danger Zones
- •6.8.2 Other Considerations
- •References
- •7: Mohs Surgery: Fixed Tissue Technique
- •Summary
- •Summary: Conclusion
- •7.2 Conclusion
- •References
- •8: Fresh Tissue Technique
- •Summary: Introduction
- •8.1 Introduction
- •Summary: The Technique
- •8.2 The Technique
- •Summary: Histologic Preparation of the Tissue
- •8.3 Histologic Preparation of the Tissue
- •Summary: Conclusion
- •8.4 Conclusion
- •References
- •Summary: Introduction
- •9.1 Introduction
- •Summary: Solid Organ Transplant Recipients
- •9.2 Solid Organ Transplant Recipients
- •Summary: HIV/AIDS
- •9.3 HIV/AIDS
- •Summary: Cutaneous Neoplasms
- •9.4 Cutaneous Neoplasms
- •9.4.1 Actinic Keratoses and Squamous Cell Carcinoma
- •9.4.2 Basal Cell Carcinoma
- •9.4.3 Melanoma
- •9.4.4 Merkel Cell Carcinoma
- •9.4.5 Kaposi Sarcoma
- •9.5.1 Preoperative Evaluation
- •9.5.2 Antibiotic Prophylaxis
- •9.5.3 Wound Healing
- •9.5.4 Selection of Therapeutic Modality
- •9.5.5 Follow-Up
- •Summary: Conclusion
- •9.6 Conclusion
- •References
- •10: Mohs Micrographic Surgery in Ethnic Skin
- •10.1 Introduction
- •Summary: Histologic Differences in Skin of Color
- •Summary: Basal Cell Carcinoma (BCC)
- •10.3 Basal Cell Carcinoma (BCC)
- •Summary: Squamous Cell Carcinoma (SCC)
- •10.4 Squamous Cell Carcinoma (SCC)
- •Summary: Malignant Melanoma (MM)
- •10.5 Malignant Melanoma (MM)
- •Summary: Conclusion
- •10.7 Conclusion
- •References
- •Summary: The Operating Room (OR)
- •11.2 The Operating Room (OR)
- •Summary: Surgical Waiting Room
- •11.3 Surgical Waiting Room
- •Summary: The Histopathology Laboratory
- •11.4 The Histopathology Laboratory
- •Summary: Grossing and Inking
- •11.5 Grossing and Inking
- •11.6 Embedding and Mounting Tissue and the Cryostat
- •Summary: Staining Frozen Sections
- •11.7 Staining Frozen Sections
- •Summary: Slide Reading
- •11.8 Slide Reading
- •Summary: Conclusion
- •11.10 Conclusion
- •References
- •Summary: Tissue Transport
- •12.1 Tissue Transport
- •Summary: Initial Processing
- •12.2 Initial Processing
- •Summary: Conclusion
- •12.3 Conclusion
- •Reference
- •Summary: Introduction
- •13.1 Introduction
- •13.2 Histopathologic Scanning of Mohs Slides
- •13.3 Histopathologic Recognition of Cutaneous Structures
- •13.3.1 Recognition of Epidermal and Epithelial Components and Their Neoplasia
- •13.3.1.1 The Epidermis
- •13.3.1.2 Melanocytes and the Melanocytic Lesions
- •13.3.1.4 The Pilosebaceous Unit
- •13.3.1.5 The Bulge
- •13.3.1.6 The Mantle and Sebaceous Glands
- •13.3.1.7 The Folliculocentric Basaloid Proliferations (FBP)
- •13.3.2 Histopathologic Recognition of Dermal Components
- •13.3.2.1 Fibrous Tissue, Desmoplasia, and Nerves
- •13.3.2.2 The Dermal Microvascular Unit
- •13.3.2.3 Dermal Muscles, Cartilage, and Subcutaneous Adipose Tissue
- •Summary: Conclusion
- •13.4 Conclusion
- •References
- •Summary: History
- •14.1 History
- •Summary: Preexamination Process
- •14.4 Preexamination Process
- •Summary: Examination Process
- •14.5 Examination Process
- •Summary: Postexamination Process
- •14.6 Postexamination Process
- •Summary: Conclusion
- •14.7 Conclusion
- •References
- •15: Immunostains
- •Summary: Introduction
- •15.1 Introduction
- •Summary: Melanoma
- •15.3 Melanoma
- •15.4 Basal Cell and Squamous Cell Carcinoma
- •Summary: Other Rare Tumors
- •15.7 Other Rare Tumors
- •15.7.1 Granular Cell Tumor
- •15.7.2 Primary Mucinous Carcinoma
- •15.7.3 Trichilemmal Carcinoma
- •Summary: Conclusions
- •15.8 Conclusions
- •References
- •16: Basal Cell Carcinoma
- •Summary: Introduction
- •16.1 Introduction
- •Summary: Etiology
- •16.2 Etiology
- •16.3 Histological Findings Using Horizontal Frozen Sections
- •Summary: Non-cancerous Conditions That May Be Histologically Similar to BCC
- •Summary: Cancerous Conditions That May Be Histologically Similar to BCC
- •16.6 Adnexal Differentiation Observed in BCC
- •Summary: Basosquamous Differentiation
- •16.7 Basosquamous Differentiation
- •Summary: Therapeutic Options
- •16.8 Therapeutic Options
- •Summary: Mohs Micrographic Surgery
- •16.9 Mohs Micrographic Surgery
- •Summary: Conclusions
- •16.10 Conclusion
- •References
- •17: Squamous Cell Carcinoma
- •Summary: Introduction
- •17.1 Introduction
- •Summary: Pathophysiology (Risk Factors for SCC Development)
- •17.2 Pathophysiology (Risk Factors for SCC Development)
- •17.2.1 Ultraviolet Light
- •17.2.2 Human Papilloma Virus
- •17.2.3 Molecular and Genetic Factors Impacting SCC Development
- •Summary: Clinical Disease Spectrum
- •17.3 Clinical Disease Spectrum
- •17.3.1 Actinic Keratosis
- •17.3.2 Squamous Cell Carcinoma In Situ
- •17.3.3 Invasive Squamous Cell Carcinoma
- •17.3.4 Differential Diagnosis
- •17.4 Management of Invasive Cutaneous SCC
- •17.4.1 Surgical Options
- •17.4.2 Radiation Therapy as Primary Therapy
- •17.5.4 Surgical Management
- •17.5.5 Radiation as Primary Therapy
- •17.5.6 Adjuvant Therapy
- •17.5.7 Assessment of Immune Status
- •17.5.8 Follow-Up for High-Risk SCC Patients
- •Summary: Treatment of Field Cancerization
- •17.6 Treatment of Field Cancerization
- •Summary: Conclusions
- •17.7 Conclusions
- •References
- •Summary: Introduction
- •18.1 Introduction
- •Summary: Surgical Treatment of Melanoma
- •18.2 Surgical Treatment of Melanoma
- •Summary: MMS for Cutaneous Melanoma
- •18.3 MMS for Cutaneous Melanoma
- •Summary: Application of MMS for the Treatment of Cutaneous Melanoma: IHC Stains
- •18.4 Application of MMS for the Treatment of Cutaneous Melanoma
- •18.4.1 IHC Stains
- •18.4.2 Technical Application of MMS and Interpretation of IHC Stains
- •Summary: Conclusion
- •18.5 Conclusion
- •References
- •19.1 Introduction
- •Summary: Epidemiology
- •19.2 Epidemiology
- •Summary: Pathogenesis
- •19.3 Pathogenesis
- •Summary: Clinical Features
- •19.4 Clinical Features
- •Summary: Pathology
- •19.5 Pathology
- •Summary: Differential Diagnose
- •19.6 Differential Diagnoses
- •Summary: Management
- •19.7 Management
- •19.7.1 Surgery
- •19.7.1.1 Wide Local Excision
- •19.7.1.2 Mohs Micrographic Surgery
- •19.7.2 Radiotherapy
- •19.7.3 Molecularly Targeted Therapy
- •19.7.4 Imaging Studies
- •Summary: Prognosis
- •19.8 Prognosis
- •Summary: Conclusion
- •19.9 Conclusion
- •20: Microcystic Adnexal Carcinoma
- •Summary: Introduction
- •20.1 Introduction
- •Summary: Epidemiology
- •20.2 Epidemiology
- •Summary: Pathogenesis
- •20.3 Pathogenesis
- •Summary: Clinical Features and Diagnosis
- •20.4 Clinical Features and Diagnosis
- •Summary: Histopathological Features
- •20.5 Histopathological Features
- •Summary: Treatment
- •20.6 Treatment
- •Summary: Prognosis and Follow-Up
- •References
- •21: Atypical Fibroxanthoma
- •Summary: History
- •21.1 History
- •Summary: Pathogenesis
- •21.2 Pathogenesis
- •Summary: Clinical Features
- •21.3 Clinical Features
- •Summary: Pathology
- •21.4 Pathology
- •Summary: Treatment
- •21.5 Treatment
- •Summary: Conclusion
- •21.6 Conclusion
- •References
- •22: Extramammary Paget Disease
- •Summary: Introduction
- •22.1 Introduction
- •Summary: History of EMPD and Epidemiology
- •22.2 History of EMPD and Epidemiology
- •22.2.1 History of EMPD
- •22.2.2 Epidemiology
- •22.2.3 Associated Malignancies
- •22.2.4 Affected Areas: Sites with Apocrine Glands
- •22.3 Clinical Presentation and Natural History
- •22.3.1 Clinical Presentation
- •22.3.2 Prognosis
- •Summary: Clinical Subtypes
- •22.4 Clinical Subtypes
- •22.4.1 Vulvar EMPD
- •22.4.2 Perianal EMPD
- •22.4.3 Penoscrotal EMPD
- •22.4.4 Triple EMPD
- •22.4.5 Unifocal or Multifocal Disease?
- •22.5 Diagnosing EMPD/Disease Pathophysiology
- •22.5.1 Histology
- •22.5.2 Histologic Differential Diagnosis
- •22.5.3 Evaluation for Internal Malignancy
- •22.5.4 Sentinel Lymph Node Biopsy
- •22.5.5 Pathophysiology
- •22.5.6 Cell of Origin
- •Summary: EMPD Treatment
- •22.6 EMPD Treatment
- •22.6.1 Wide Local Excision and Recommended Margin
- •22.6.2 Time to Recurrence
- •22.6.2.1 Mohs Surgery for EMPD
- •22.6.3 Mohs Surgery with CK7 Immunostaining
- •22.6.4 Peripheral Mohs Surgery
- •22.6.5 Scouting Biopsies
- •Summary: Alternative Treatment Options
- •22.7 Alternative Treatment Options
- •22.7.2 Photodynamic Therapy
- •22.7.3 Laser Vaporization
- •22.7.4 Radiation Therapy
- •22.7.5 Chemotherapy for EMPD: Local and Systemic
- •Summary: Conclusion
- •22.8 Conclusion
- •References
- •23: Leiomyosarcoma
- •Summary: Introduction
- •23.1 Introduction
- •Summary: Clinical Features
- •23.2 Clinical Features
- •Summary: Histologic Features
- •23.3 Histologic Features
- •Summary: Prognosis
- •23.4 Prognosis
- •23.4.1 Treatment
- •23.4.2 Mohs Micrographic Surgery (MMS)
- •Summary: Conclusion
- •23.5 Conclusion
- •References
- •24: Merkel Cell Carcinoma
- •Summary: Overview of Merkel Cell Carcinoma
- •24.1 Overview of Merkel Cell Carcinoma
- •Summary: Diagnosis of Merkel Cell Carcinoma
- •24.2 Diagnosis of Merkel Cell Carcinoma
- •24.2.1 Clinical Features
- •24.2.2 Pathology
- •24.2.3 Differential Diagnosis
- •Summary: Management of Merkel Cell Carcinoma
- •24.3 Management of Merkel Cell Carcinoma
- •24.3.1 Patient Evaluation and Staging
- •24.3.1.1 No Clinical Nodal Involvement
- •24.3.1.2 Clinical Nodal Involvement
- •24.3.1.3 Metastatic Disease
- •24.3.2 Treatment
- •24.3.3 Prognosis
- •24.4 Mohs Micrographic Surgery and Merkel Cell Carcinoma
- •Summary: Conclusion
- •24.5 Conclusion
- •References
- •25: Selected Sweat Gland Carcinomas
- •Summary: Porocarcinoma
- •25.1 Porocarcinoma
- •Summary: Hidradenocarcinoma
- •25.2 Hidradenocarcinoma
- •Summary: Cutaneous Adenoid Cystic Carcinoma
- •25.3 Cutaneous Adenoid Cystic Carcinoma
- •Summary: Malignant Cylindroma
- •25.5 Malignant Cylindroma
- •Summary: Mucinous Carcinoma of the Skin
- •25.6 Mucinous Carcinoma of the Skin
- •Summary: Conclusion
- •25.7 Conclusion
- •References
- •Porocarcinoma
- •Hidradenocarcinoma
- •Cutaneous Adenoid Cystic Carcinoma
- •Spiradenocarcinoma
- •Malignant Cylindroma
- •Mucinous Carcinoma of the Skin
- •26: Sebaceous Carcinoma
- •Summary: Introduction
- •26.1 Introduction
- •26.1.1 Origin
- •26.1.2 History
- •26.1.3 Extraorbital Sites
- •26.1.4 Incidence
- •Summary: Demographics
- •26.2 Demographics
- •26.2.1 Age, Sex, Irradiation, Race
- •26.2.3 Human Papillomavirus (HPV)
- •26.2.4 Other Risk Factors
- •Summary: Clinical Presentation
- •26.3 Clinical Presentation
- •Summary: Histopathology
- •26.4 Histopathology
- •26.4.1 Pattern of Differentiation
- •26.4.2 Degree of Differentiation
- •26.4.3 Mechanisms of Invasion
- •26.4.3.1 Direct Invasion
- •26.4.3.2 Pagetoid Spread
- •26.4.3.3 Multicentric Origin
- •26.4.4 Clinicopathologic Features of Poor Outcomes
- •Summary: Treatment
- •26.5 Treatment
- •26.5.1 Biopsy Procedure
- •26.5.2 Conjunctiva Mapped Biopsies
- •26.5.3 Oil Red O and Sudan Black Stains
- •26.5.4 Traditional Wide Local Excision (WLE)
- •26.5.5 Mohs Micrographic Surgery
- •26.5.6 Surgical and Tissue Processing Issues
- •26.5.7 Frozen Sections
- •26.5.9 Exenteration
- •26.5.10 Mohs Surgery, Practical Points
- •26.5.11 Corneal Protection Measures
- •Summary: Follow-Up Considerations
- •26.6.1 Local Recurrence
- •26.6.2 Metastasis
- •26.6.3 Distant Metastasis
- •26.6.4 Sentinel Lymph Node (SLN)
- •Summary: Conclusion
- •26.7 Conclusion
- •References
- •Summary: Introduction
- •27.1 Introduction
- •Summary: Review of the Relevant Anatomy
- •27.2 Review of the Relevant Anatomy
- •27.3 Anatomical Considerations When Using Mohs Micrographic Surgery in the Periorbital Region
- •Summary: Periorbital BCC
- •27.4 Periorbital BCC
- •Summary: Periorbital SCC
- •27.5 Periorbital SCC
- •Summary: Other Tumors
- •27.6 Other Tumors
- •Summary: Conclusion
- •27.7 Conclusion
- •References
- •28.1 Introduction
- •Summary: Introduction
- •Summary: Anatomy
- •28.2 Anatomy
- •28.2.1 Nail Matrix
- •28.2.2 Nail Plate
- •28.2.3 Supporting Portion: Nail Bed and Phalangeal Bone
- •28.2.4 Nail Folds
- •28.2.5 Cuticle
- •28.2.6 Hyponychium
- •28.2.7 Arteries and Nerves of the Digit
- •28.2.8 Extensor Tendon
- •Summary: Tumors
- •28.3 Tumors
- •28.3.1 Squamous Cell Carcinoma
- •28.3.3 Melanoma
- •28.3.4 Basal Cell Carcinoma
- •28.3.5 Warts
- •Summary: Mohs Technique
- •28.4 Mohs Technique
- •28.4.1 Preoperative Evaluation
- •28.4.2 Anesthesia
- •28.4.3 Instruments
- •28.4.4 Preoperative Preparation
- •28.4.5 Mohs Technique
- •28.4.6 Dressings and Postoperative Care
- •Summary: Complications
- •28.5 Complications
- •Summary: Conclusions
- •28.6 Conclusions
- •References
- •29: Genitalia
- •Summary: Introduction
- •29.1 Introduction
- •Summary: Surgical Technique
- •29.2 Surgical Technique
- •Summary: Reconstruction
- •29.3 Reconstruction
- •Summary: Common Genital Lesions Treated with Mohs Micrographic Surgery
- •29.4.1 Basal Cell Carcinoma
- •29.4.3 In Situ and Invasive Malignant Melanomas
- •29.4.6 Granular Cell Tumor
- •29.4.8 Leukemias and Lymphoblastomas
- •29.4.9 Langerhans Cell Histiocytosis
- •29.4.10 Haemolymphangioma
- •Summary: Conclusions
- •29.5 Conclusions
- •References
- •Summary: Introduction
- •30.1 Introduction
- •Summary: Innervation of the Face and Scalp
- •30.2 Innervation of the Face and Scalp
- •30.2.2 Sensory Innervation of the Face and Scalp
- •30.2.3 Innervation of the Ear
- •Summary: Muscles of Facial Expression
- •30.3 Muscles of Facial Expression
- •30.3.1 Muscles of the Forehead
- •30.3.2 Muscles of the Periorbital Region
- •30.3.3 Muscles of the Nose
- •30.3.4 Muscles of the Cheek and Perioral Region
- •30.4 Soft Tissue Components of the Scalp and Face
- •30.4.1 Scalp
- •30.4.2 Face
- •30.5 Bony and Cartilaginous Structures of the Face and Scalp
- •30.5.1 Bony Landmarks
- •30.5.2 Cartilaginous Structures
- •30.6 Muscosa of the Lip, Nose, and Conjunctiva
- •Summary: Conclusion
- •30.8 Conclusion
- •References
- •Summary: Bleeding Complications
- •31.1 Bleeding Complications
- •Summary: Infectious Complications
- •31.2 Infectious Complications
- •Summary: Nerve Injury
- •31.3 Nerve Injury
- •Summary: Tumor Recurrence
- •31.4 Tumor Recurrence
- •Summary: Medication Complications
- •31.5 Medication Complications
- •Summary: Recently Described Complications
- •31.6 Recently Described Complications
- •Summary: Conclusion
- •31.7 Conclusion
- •References
- •32.1.1 Upper Eyelid
- •32.1.1.1 Primary Closure
- •32.1.1.2 Myocutaneous Advancement Flap
- •32.1.1.3 Full-Thickness Skin Graft
- •32.1.2 Lower Eyelid
- •32.1.2.1 Primary Closure
- •32.1.2.2 Myocutaneous Advancement Flap
- •32.1.2.3 Ellipse Sliding Flap
- •32.1.2.4 Unipedicle Flap
- •32.1.2.5 Skin Graft
- •Summary: Full-Thickness Eyelid Defects
- •32.2.1 Upper Eyelid
- •32.2.1.1 Primary Closure
- •32.2.2 Lower Eyelid
- •32.2.2.1 Primary Closure
- •Summary: Special Circumstances
- •32.3 Special Circumstances
- •32.3.1 Medial Canthal Defect
- •32.3.1.1 Glabellar Flap
- •Summary: Postoperative Care and Follow-up
- •Summary: Conclusion
- •32.5 Conclusion
- •References
- •33: Flaps
- •Summary: Introduction
- •33.1 Introduction
- •Summary: Risks and Precautions
- •33.2 Risks and Precautions
- •Summary: Flap Design and Execution
- •33.3 Flap Design and Execution
- •Summary: Advancement Flaps
- •33.4 Advancement Flaps
- •33.4.1 Single Advancement
- •33.4.2 Bilateral Advancement
- •33.4.3 Crescentic Advancement
- •33.4.4 Island Pedicle
- •Summary: Rotation Flaps
- •33.5 Rotation Flaps
- •33.5.1 Dorsal Nasal Rotation
- •33.5.2 Bilateral Rotation
- •Summary: Transposition Flaps
- •33.6 Transposition Flaps
- •33.6.1 Rhombic
- •33.6.1.1 Dufourmental
- •33.6.1.2 Thirty-Degree Angle Webster Flap
- •33.6.2 The Banner Flap
- •33.6.3 Bilobed Flap
- •Summary: Interpolation Flaps
- •33.7 Interpolation Flaps
- •33.7.1 Paramedian Forehead
- •33.7.2 Nasolabial Interpolation
- •33.7.4 Retroauricular
- •Summary: Postoperative Care
- •33.8 Postoperative Care
- •Summary: Complications
- •33.9 Complications
- •Summary: Monitoring and Follow-Up
- •33.10 Monitoring and Follow-Up
- •Summary: Conclusion
- •33.11 Conclusion
- •References
- •34: Skin Grafting
- •Summary: Introduction
- •34.1 Introduction
- •Summary: Physiology
- •34.2 Physiology
- •Summary: Indications
- •34.3 Indications
- •Summary: Preoperative Assessment
- •34.4 Preoperative Assessment
- •Summary: Site Selection
- •34.5 Site Selection
- •Summary: Full-Thickness Skin Grafts
- •34.6.1 Graft Harvesting
- •34.6.2 Graft Fixation
- •Summary: Split-Thickness Skin Grafts
- •34.7.1 Graft Harvest
- •34.7.2 Graft Fixation
- •Summary: Composite Grafts
- •34.8 Composite Grafts
- •Summary: Postoperative Instructions
- •34.9 Postoperative Instructions
- •34.9.1 FTSG
- •34.9.2 STSG
- •Summary: Cultured Skin Substitutes
- •34.10 Cultured Skin Substitutes
- •34.10.1 Epidermal
- •34.10.2 Dermal
- •34.10.3 Bilayered
- •34.10.4 Graft Fixation
- •34.10.5 Postoperative Instructions
- •Summary: Graft Failure
- •34.11 Graft Failure
- •Summary: Conclusion
- •34.12 Conclusion
- •References
- •Summary: Introduction
- •35.1 Introduction
- •Summary: Side to Side Closures
- •35.2 Side to Side Closures
- •Summary: Suturing of the Wounds
- •35.3 Suturing of the Wounds
- •Summary: Cosmetic Subunits
- •35.4 Cosmetic Subunits
- •Summary: Complex Facial Defects
- •35.5 Complex Facial Defects
- •Summary: General Considerations
- •35.6 General Considerations
- •Summary: Complications
- •35.7 Complications
- •Summary: Conclusion
- •35.8 Conclusion
- •References
- •36: Prosthetic Rehabilitation
- •Summary: Introduction
- •36.1 Introduction
- •Summary: Moulage Impression Procedure
- •36.2 Moulage Impression Procedure
- •Summary: Adhesive Retained Nasal Prosthesis
- •36.3 Adhesive Retained Nasal Prosthesis
- •Summary: Adhesive Retained Auricular Prosthesis
- •36.4 Adhesive Retained Auricular Prosthesis
- •Summary: Adhesive and/or Mechanically Retained Orbital Prosthesis
- •36.5 Adhesive and/or Mechanically Retained Orbital Prosthesis
- •36.6 Midface/Multisite Craniofacial Prosthesis
- •36.7 Considerations Regarding Implant Retained Craniofacial Prosthesis
- •Summary: Implant Retained Nasal Prosthesis
- •36.8 Implant Retained Nasal Prosthesis
- •Summary: Implant Retained Auricular Prosthesis
- •Summary: Implant Retained Orbital Prosthesis
- •36.10 Implant Retained Orbital Prosthesis
- •36.11 Multisite Implant Retained Craniofacial Prosthesis
- •Summary: Conclusion
- •36.12 Conclusion
- •References
- •Summary: Adjuvant Treatment with Imiquimod
- •37.1 Adjuvant Treatment with Imiquimod
- •Summary: Adjuvant Treatment with Radiation
- •37.2 Adjuvant Treatment with Radiation
- •37.3 Nonsurgical Treatment of Aggressive Basal Cell Carcinoma
- •Summary: Photodynamic Therapy
- •37.5 Photodynamic Therapy
- •Summary: Off-Label Intraoperative PDT with Topical and Intralesional Aminolevulinic Acid on SCC of the Penis
- •Summary: Conclusion
- •37.7 Conclusion
- •References
- •References
- •39: Establishing a Mohs Practice
- •Summary: General Considerations
- •39.1 General Considerations
- •Summary: The Electronic Medical Record
- •39.2 The Electronic Medical Record
- •39.3 Credentials, Licensure, and Malpractice Insurance
- •Summary: Quality Assurance
- •39.4 Quality Assurance
- •Summary: Cameras
- •39.5 Cameras
- •Summary: Care of Instruments
- •39.6 Care of Instruments
- •Summary: Work Rooms
- •39.7 Work Rooms
- •Summary: Microscopes
- •39.8 Microscopes
- •Summary: Instrumentation
- •39.9 Instrumentation
- •Summary: Regulations
- •39.10 Regulations
- •Summary: Reception Area
- •39.11 Reception Area
- •Summary: Waiting Area
- •39.12 Waiting Area
- •Summary: Exam/Surgery Rooms
- •39.13 Exam/Surgery Rooms
- •Summary: Nurses Work Station
- •39.15 Nurses Work Station
- •Summary: Personnel
- •39.16 Personnel
- •Summary: The Laboratory
- •39.17 The Laboratory
- •Summary: Space
- •39.18 Space
- •Summary: Personal Protective Equipment
- •39.19 Personal Protective Equipment
- •Summary: Mapping and Grossing the Tissue
- •39.20 Mapping and Grossing the Tissue
- •Summary: Devices to Aid Embedding
- •39.22 Devices to Aid Embedding
- •Summary: Cryosectioning Tissue
- •39.23 Cryosectioning Tissue
- •Summary: Staining
- •39.24 Staining
- •Summary: Coverslipping
- •39.25 Coverslipping
- •Summary: At the End of the Day
- •Summary: Permanent Sections and Immunostains
- •39.27 Permanent Sections and Immunostains
- •39.27.1 Immunostains
- •Summary: Training of Laboratory Technicians
- •39.28 Training of Laboratory Technicians
- •Summary: Inspections and Regulations
- •39.29 Inspections and Regulations
- •Summary: Marketing
- •39.30 Marketing
- •Summary: Preoperative Consultation
- •39.31 Preoperative Consultation
- •Summary: Brochures and Handouts
- •39.32 Brochures and Handouts
- •Summary: Operative Consents
- •39.33 Operative Consents
- •Summary: Conclusion
- •39.34 Conclusion
- •Reference
- •Summary: The Brazilian Perspective
- •40.1 The Brazilian Perspective
- •Summary: The Argentinean Perspective
- •40.2 The Argentinean Perspective
- •Summary: Conclusion
- •40.3 Conclusion
- •References
- •References
- •42.1 Characteristics of Skin Cancers in East Asia
- •Summary: Treatment of Skin Cancers in East Asia
- •42.2 Treatment of Skin Cancers in East Asia
- •42.2.1 Standard Treatment of Skin Cancers
- •42.2.2 Present State of MMS in East Asia
- •Summary: Conclusion
- •42.3 Conclusion
- •References
- •43.1 Introduction and Brief History of Mohs Micrographic Surgery in Australia and New Zealand
- •43.2 Work Practices of Australian Mohs Surgeons
- •43.2.1 Background
- •43.2.2 Mohs Caseload
- •43.2.3 Conclusion
- •Summary: The Australian Mohs Database
- •43.3 The Australian Mohs Database
- •43.3.1 Introduction
- •43.3.3 Squamous Cell Carcinoma Treated with Mohs Micrographic Surgery in Australia
- •43.3.4 Conclusion
- •43.4.1 Mohs for Invasive SCC and SCC In Situ of the Nail Apparatus
- •43.4.2 Extensive Use of Secondary Wound Healing in a Knowledgeable Patient
- •Summary: Mohs Surgery in New Zealand
- •43.5 Mohs Surgery in New Zealand
- •Summary: Conclusions
- •43.6 Conclusions
- •References
- •Summary: Introduction
- •44.1 Introduction
- •Summary: Patient Safety Considerations
- •44.2 Patient Safety Considerations
- •44.2.1 The Preoperative Visit
- •44.2.2 Past Medical History and Physical Exam
- •Summary: Information for Patients
- •44.3 Information for Patients
- •44.3.1 Cardiovascular Complications
- •44.3.2 Antibiotic Prophylaxis
- •44.3.3 Anticoagulation
- •44.3.4 Anesthesia
- •44.3.5 Allergies
- •Summary: Planning for the Surgical Day
- •44.4 Planning for the Surgical Day
- •44.5.1 Patient Emergencies
- •44.5.2 Staff Safety
- •44.5.3 Mohs Lab Safety
- •Summary: Conclusion
- •44.6 Conclusion
- •References
- •Summary: Introduction
- •45.1 Introduction
- •Summary: The Four Elements
- •45.2 The Four Elements
- •Summary: Standard of Care
- •45.3 Standard of Care
- •Summary: Clinical Guidelines
- •45.4 Clinical Guidelines
- •Summary: Legal Relevance
- •45.5 Legal Relevance
- •Summary: Case Example 1
- •45.6 Case Example 1
- •Summary: Case Example 2
- •45.7 Case Example 2
- •Summary: Ethical Relevance
- •45.8 Ethical Relevance
- •45.8.1 Actinic Keratoses
- •45.8.1.1 Invasive Techniques
- •Cryosurgery
- •Curettage and Electrodessication
- •Dermabrasion and Chemical Peels
- •Carbon Dioxide or Erbium:YAG Laser Ablation
- •45.8.1.2 Non-invasive Techniques
- •Topical Chemotherapy
- •Photodynamic Therapy (PDT)
- •References
- •Summary: Introduction
- •46.1 Introduction
- •Summary: Medical Malpractice
- •46.2 Medical Malpractice
- •46.2.1 Duty
- •46.2.2 Breach of Duty
- •46.2.3 Causation
- •46.2.4 Damages
- •Summary: Consent/Refusal for Treatment
- •46.3 Consent/Refusal for Treatment
- •46.3.1 Implied Consent
- •46.3.2 Express Consent
- •46.3.3 Informed Consent
- •46.3.3.2 Reasonable Patient Standard/Legal Standard
- •Summary: Medical Records
- •46.4 Medical Records
- •46.5 Complications in Skin Cancer Treatment
- •Summary: Rectifying Adverse Events: Key Steps
- •46.6 Rectifying Adverse Events: Key Steps
- •46.6.1 Build Trust
- •46.6.2 Take an Active Role
- •46.6.3 Help the Patient
- •46.6.4 Enlist Help from Others
- •46.6.5 Be Available
- •46.6.6 Contact the Malpractice Carrier
- •46.6.7 Preserve Evidence
- •46.6.8 Document the Facts of the Event
- •Summary: Conclusion
- •46.7 Conclusion
- •References
- •Summary: Introduction
- •47.1 Introduction
- •47.3 The Potential Detrimental Impact of Mohs Surgery
- •47.3.4 Negative Self-Image
- •47.4.1 Social Phobia
- •47.4.2 Generalized Anxiety Disorder
- •47.4.3 Depression
- •Summary: Conclusion
- •47.5 Conclusion
- •References
- •Index
152 |
J.S. Youse et al. |
|
|
Fig. 14.1 An overview of the entire total testing process, also called the path of workflow. Any step in the process may lead to medical errors. Note that the process always begins and ends with patient care (Adapted from Barr and Schumacher [12]. Reproduced with permission of The McGraw-Hill Companies)
resources dedicated to continually improving patient care and quality from medical laboratories, including a quality management system focused on path of workflow.
A thorough understanding of the path of workflow in a clinical laboratory, also called the testing process, is essential to understanding the importance of proper tissue specimen documentation, record keeping, and storage. The path of workflow allows clinical laboratories to provide quality results and reduce medical errors. Regardless of the specimen, whether a blood sample or a Mohs layer, a defined sequential process is followed to transform a physician’s order into a usable result. This process is called the path of workflow, and it is often subdivided into three separate processes: preexamination, examination, and postexamination. All of the specific policies and procedures for a given laboratory should stem from this simple path of workflow. Development of an organized, thorough, and well-understood path of workflow is the foundation of quality laboratory results. An overview of the path of workflow, also known as the total testing process, is shown in Fig. 14.1 [12]. During inspections, demonstration of appropriate documentation, understanding, training, and execution of a well-organized path of workflow is important to obtaining and maintaining accreditation.
Consider the path of workflow for an MMS practice. All the processes from the time of patient checkin through the preparation of tissue slides make up the preexamination process. The microscopic evaluation of Mohs frozen tissue sections on glass slides is the examination step. The recording, documentation, and notification of results, as well as the storage of slides and tissue, are part of the postexamination process. The American Academy of Dermatology (AAD) has prepared a sample policy and procedure manual that details the individual steps in the path of workflow for an MMS practice. This document is available for AAD members on the AAD Web site (www.aad.org/pm/ compliance/clia). Pertinent features for each of these processes in the path of workflow specific to an MMS surgical practice are discussed next.
Summary: Preexamination Process
•Preexamination process involves collection, transport, receipt, and initial processing of tissue specimens.
•Rate of medical errors is higher in the preexamination process.
•Medical errors occurring in the preexamination process are often preventable.
14 Tissue Specimen Documentation, Record Keeping, and Sample Storage |
153 |
|
|
Clinical laboratory examination key processes
Preexamination |
|
|
Examination |
|
Postexamination |
process |
|
|
process |
|
process |
|
|
|
|
|
|
Examination ordering
sample collection
sample transport
sample receipt/processing
Fig. 14.2 Overview of the preexamination process with permission from NCCLS [10]
Steps in the preexamination process for a mohs surgery patient
Examination ordering
1.Patient check-in and identity verification
2.Review and confirm pathology diagnosis and biopsy location and other pertinent clinical data
3.Verify patient identity on printed patient labels and orders
Sample collection
1. Preparation of patient and surgical site
2 Verify patient identification
3.Removal of Mohs tissue layer with correct orientation
4.Preparation of tissue and Mohs map
5.Proper labeling of tissue container and Mohs map
14.4Preexamination Process
The preexamination process includes all of the processes from ordering of the examination to collection, transport, receipt, and processing of the specimen (Fig. 14.2). Each step in this process requires appropriate documentation. A example of the preexamination process for a Mohs surgery patient is shown in Fig. 14.3.
The rate of medical errors for the preexamination process is higher than that for the rest of examination process [13, 14]. Decreasing errors in the preexamination process has become the focus of system-based improvement initiatives and quality measures. The focus on the preexamination process is partly because these errors are more common and can potentially lead to serious negative outcomes and partly because many errors are preventable by modifying the system of specimen collection. Preexamination errors include those related to failure to verify patient identity and incorrect labeling of specimens. Medical errors related to mislabeling of specimens represents a common, serious, and often preventable error. Specimen labeling errors are estimated to occur at rates of 0.1–5% [13–16]. A recent prospective trial found a rate of 4.3 per 1,000 for mislabeling of surgical specimens over a 6-month period. Skin specimens were the second most common tissue involved with labeling errors. Compared with specimens obtained in an operating room, specimens obtained in the outpatient setting were more likely to be mislabeled with the incorrect patient, site, or laterality or to involve an empty container [14]. The potential for patient harm related to mislabeled specimens may result from treatment delay, repeat biopsy procedures, unnecessary treatment, or procedures to the wrong site or wrong patient.
In an effort to reduce these types of errors, the Joint Commission requires the use of two patient identifiers in specimen labels and a preoperative Universal
Sample transport
1.Ensure proper and safe packaging of specimen
2.Safe delivery of properly labeled specimen and Mohs map from surgical suite to laboratory
Sample receipt and processing
1.Surgeon or nurse delivers properly labeled specimen and Mohs map to lab
2.Lab technician confirms proper labeling of specimen and documents patient identity, tissue identity and Mohs map identity and enters data in Mohs log
3.Specimens prepared frozen sectioning in the proper order
4.Frozen sections are cut and stained on properly labeled slides showing patient name, number, date and source
5.Coverslips applied and labeled slides and Mohs map brought to surgeon for examination
6.Excess tissue maintained in freezer until examination process complete
Fig. 14.3 Steps in the preexamination process for a Mohs surgery patient
Protocol consisting of a preprocedure verification process, marking of the procedure site, and performing a time-out before any procedure [17]. In addition to creation of standardized processes for specimen collection and labeling, procedures such as use of radiofrequency identification of specimens, introduction of a paperless pathology requisition process, and confirmation of correct site and correct patient by two health care providers have been shown in other studies to decrease errors [11, 18]. CLSI guidelines and standards with sample documents are available to assist with development of standardized labeling and identification systems for both patients and specimens [19–21]. These documents set standards for labels including exact specifications on the content, size, and arrangement of clinical data on the label. A sample label adhering to these recommendations is shown in Fig. 14.4.
154 |
J.S. Youse et al. |
|
|
Fig. 14.4 Sample Mayo Clinic patient label. This sample patient label illustrates key features of a well-designed patient label highlighted by standardized arrangement of important patient data. Standardized labeling is a key component of the preexamination process [19–21] (Figure used by permission of Mayo Foundation for Medical Education and Research. All rights reserved)
Some aspects of the preexamination process deserve special attention in relation to MMS, including identification of a previous biopsy site. The time between initial biopsy and MMS treatment is often several weeks. Identification of biopsy sites that are well healed is often difficult. Documentation of the exact anatomic location of the biopsy site is often lacking. To prevent or minimize this problem, we recommend photographic documentation of biopsy sites and modifying the documentation of the biopsy site to include a measurement from a fixed anatomic point (e.g., “biopsy site is located 6 cm in the 9 o’clock position from the tragus”). The use of photography to document biopsy sites has been shown to decrease errors in biopsy site identification [22]. After drawing the proposed surgical plan with a surgical marker at the MMS appointment, it is recommended to verbally and visually verify the biopsy site with the patient using a handheld mirror.
Summary: Examination Process
•Examination process involves the evaluation of a tissue specimen and recording of results.
•Special emphasis on MMS examination phase given the unique importance of tissue orientation in recording results and because a single provider is obtaining, evaluating tissue, recording results, and then providing treatment based upon those results.
Clinical laboratory examination key processes
Preexamination |
|
|
Examination |
|
|
Postexamination |
process |
|
|
process |
|
|
process |
|
|
|
|
|
|
|
Examination
Results review and follow-up
Interpretation 
Fig. 14.5 Overview of the examination process with permission from NCCLS [10]
14.5Examination Process
The examination process must provide accurate and reliable results in order to be successful. The examination process in MMS involves the surgeon evaluating the frozen sections and recording the results of the evaluation on the Mohs map. The process itself is straightforward and involves two steps: evaluation and recording (Fig. 14.5). As has been emphasized previously, special attention should be given to continuing to verify the identity of the specimen and ensure that it matches the identity on the Mohs map with each handoff. The most important and complex step in the examination process is the accurate evaluation of Mohs frozen section histopathologic samples for the presence or absence of tumor. This examination process is somewhat unique in MMS for several reasons. First, correct orientation of the tissue is absolutely vital to treatment. Second, the surgeon is often the only person evaluating the slides, marking results on the Mohs map, and providing treatment for a patient with skin cancer on the basis of the results. This places much responsibility on the surgeon to carefully examine each slide for the presence or absence of tumor, to determine the accurate location and orientation within the tissue block, and to properly record and orient the results on the Mohs map.
A successful Mohs surgeon must recognize the importance of these steps in the examination process for MMS (Fig. 14.6).
The process of converting the histopathologic evidence of tumor on a Mohs section both to a diagnosis and to proper recording of the tumor on the Mohs map is difficult to standardize. This complex and poorly understood process is valueless if the results are recorded on the wrong Mohs map. Thus, it is important for the Mohs surgeon to constantly verify that the
14 Tissue Specimen Documentation, Record Keeping, and Sample Storage |
155 |
|
|
Steps in the examination process for a mohs surgery patient
1.Mohs surgeon reviews stained slides and Mohs map confirmed for patient identity and adequacy of specimen preparation
2.Notifies laboratory if specimen inadequate
*Documented process for reqular and routine assessment of slides and stains and correlation of results (quality assessment)
Interpretation
1.Slides reviewed at microscope by Mohs surgeon
2.Presence or absence of residual tumor and other pertinent data on tumor location, histologic features recorded on Mohs map
3.Mohs surgeon reviews finalized Mohns map
Fig. 14.6 Steps in the examination process for a Mohs surgery patient
orientation, specimen, and Mohs map are correct. Implementation of a well-documented standardized process for regular quality control to ensure that the preparation, staining, tracking, and evaluation of specimens are consistent will limit preventable errors in the examination process. This will allow the Mohs surgeon to devote his or her full attention to the often challenging task of interpreting slides rather than wondering if the examined sections belong to the correct patient.
In our practice, quality checks are regularly performed by randomly selecting both positive and negative slides for blinded peer review by fellow MMS colleagues. Results of the quality assurance measures are recorded, and discrepancies in results undergo careful root cause analysis. Ultimately, the goal of the examination process is to produce a usable result that will guide further patient care. Once all slides have been evaluated and results have been properly recorded, the postexamination process begins.
Summary: Postexamination Process
•Postexamination process involves reporting of results and archiving of records and specimens.
•Postexamination process is streamlined in a MMS practice where results are obtained and acted upon in the same day.
Clinical postexamination key process
Preexamination |
|
Examination |
|
|
Postexamination |
|
|
process |
|
process |
|
|
process |
|
|
|
|
|
|
|
Results reporting and archive
Sample management
Fig. 14.7 Overview of the postexamination process with permission from NCCLS [10]
Steps in the postexamination process for a mohs surgery patient
Results reporting and archiving
1.Patient brought back to surgical suite
2.Nurse verifies patient identity
3.Notifies patient of results
4.Mohs surgeon reviews result of Mohs map
5.Prepares patient for repair or next Mohs layer
6.Mohs map and surgical note with all pertinent detail on patient identity, tumor type, location, size, number of Mohs layers, blocks, and other pertinent details is prepared, finalized, signed by surgeon and stored in medical record
Specimen management and storage
1.Final count and verification of all prepared Mohs sections and slides recorded in Mohs log
2.Properly labeled Mohs slides are stored in defined and standardized method to meet governmental, accreditation, and laboratory requirements
*See sample table on sample and record retention schedule
Fig. 14.8 Steps in the postexamination process for a Mohs surgery patient
14.6Postexamination Process
The postexamination process involves reporting of results and archiving of records and specimens (Fig. 14.7). This process is simplified and streamlined by the nature of MMS practice, which usually involves same-day specimen collection, processing, and notification of results overseen by one Mohs surgeon (Fig. 14.8). This same-day processing inherently simplifies the postexamination process compared with that in a large clinical laboratory that must record and interpret clinical results for critical values and have a standardized system for relaying results to a multitude of ordering providers. Thus, the most salient feature of the postexamination process for the MMS practice is
156 |
J.S. Youse et al. |
|
|
Fig. 14.9 Example of sample retention schedule with permission from NCCLS [10]. A schedule for retention of various tissue specimens. The rules for retention of tissue specimens vary according to institutional, state, and local regulations
having a system for proper retention and storage of records and specimens. Regulations regarding proper storage and retention of various tissue specimens and associated records vary by state law, accrediting organization, and institution. Examples of tissue sample and document retention schedules are shown in Figs. 14.9 and 14.10.
In our practice, photographs of the treated area(s) are obtained before and after treatment and after repair. The patient photographs and the finalized Mohs map are double-checked for correct labeling and then scanned and loaded into each patient’s electronic medical record for permanent storage. An MMS surgical note also is entered, which contains all pertinent
14 Tissue Specimen Documentation, Record Keeping, and Sample Storage |
157 |
|
|
Fig. 14.10 Example of record retention schedule with permission from NCCLS [10]. Similar to rules regarding retentions of specimens, the rules for retention of records vary according to institutional, state, and local regulations
